PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brheartjLink to Publisher's site
 
Br Heart J. 1985 September; 54(3): 305–312.
PMCID: PMC481900

Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state.

Abstract

Several studies have shown symptomatic and haemodynamic improvement after the introduction of angiotensin converting enzyme inhibitors in patients with heart failure treated with diuretics. The concomitant long term effects of the new orally effective long acting angiotensin converting enzyme inhibitor, enalapril, on symptoms, exercise performance, cardiac function, arrhythmias, hormones, electrolytes, body composition, and renal function have been further assessed in a placebo controlled double blind cross over trial with treatment periods of eight weeks. Twenty patients with New York Heart Association functional class II to IV heart failure who were clinically stable on digoxin and diuretic therapy were studied. Apart from the introduction of enalapril, regular treatment was not changed over the study period; no order or period effects were noted. Enalapril treatment significantly improved functional class, symptom score for breathlessness, and exercise tolerance. Systolic blood pressure was significantly lower on enalapril treatment. Echocardiographic assessment indicated a reduction in left ventricular dimensions and an improvement in systolic time intervals. In response to enalapril, the plasma concentration of angiotensin II was reduced and that of active renin rose; plasma concentrations of aldosterone, vasopressin, and noradrenaline fell. There were significant increases in serum potassium and serum magnesium on enalapril. Glomerular filtration rate measured both by isotopic techniques and by creatinine clearance declined on enalapril while serum urea and creatinine rose and effective renal plasma flow increased. Body weight and total body sodium were unchanged indicating that there was no overall diuresis. There was a statistically insignificant rise in total body potassium, though the increase was related directly to pretreatment plasma renin (r = 0.5). On enalapril the improvement in symptoms, exercise performance, fall in plasma noradrenaline, and rise in serum potassium coincided with a decline in the frequency of ventricular extrasystoles recorded during ambulatory monitoring. Adverse effects were few. In patients with heart failure, enalapril had a beneficial effect on symptoms and functional capacity. The decline in glomerular filtration rate on enalapril may not be beneficial in early heart failure.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Arnold SB, Byrd RC, Meister W, Melmon K, Cheitlin MD, Bristow JD, Parmley WW, Chatterjee K. Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med. 1980 Dec 18;303(25):1443–1448. [PubMed]
  • Davidson C, Gibson D. Clinical significance of positive inotropic action of digoxin in patients with left ventricular disease. Br Heart J. 1973 Sep;35(9):970–976. [PMC free article] [PubMed]
  • Walsh WF, Greenberg BH. Results of long-term vasodilator therapy in patients with refractory congestive heart failure. Circulation. 1981 Sep;64(3):499–505. [PubMed]
  • Franciosa JA, Weber KT, Levine TB, Kinasewitz GT, Janicki JS, West J, Henis MM, Cohn JN. Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo. Am Heart J. 1982 Sep;104(3):587–594. [PubMed]
  • Colucci WS, Wynne J, Holman BL, Braunwald E. Long-term therapy of heart failure with prazosin: a randomized double blind trial. Am J Cardiol. 1980 Feb;45(2):337–344. [PubMed]
  • Aronow WS, Lurie M, Turbow M, Whittaker K, Van Camp S, Hughes D. Effect of prazosin vs placebo on chronic left ventricular heart failure. Circulation. 1979 Feb;59(2):344–350. [PubMed]
  • Bravo EL. Regulation of aldosterone secretion: current concepts and newer aspects. Adv Nephrol Necker Hosp. 1977;7:105–120. [PubMed]
  • Dyckner T, Wester PO. Ventricular extrasystoles and intracellular electrolytes in hypokalemic patients before and after correction of the hypokalemia. Acta Med Scand. 1978;204(5):375–379. [PubMed]
  • Holland OB, Nixon JV, Kuhnert L. Diuretic-induced ventricular ectopic activity. Am J Med. 1981 Apr;70(4):762–768. [PubMed]
  • Padfield PL, Morton JJ. Effects of angiotensin II on arginine-vasopressin in physiological and pathological situations in man. J Endocrinol. 1977 Aug;74(2):251–259. [PubMed]
  • Zimmerman BG. Adrenergic facilitation by angiotensin: does it serve a physiological function? Clin Sci (Lond) 1981 Apr;60(4):343–348. [PubMed]
  • Wenting GJ, Man in't veld AJ, Woittiez AJ, Boomsma F, Laird-Meeter K, Simoons ML, Hugenholtz PG, Schalekamp MA. Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone. Br Heart J. 1983 Jan;49(1):65–76. [PMC free article] [PubMed]
  • Campbell BC, Sturani A, Reid JL. Evidence of parasympathetic activity of the angiotensin converting enzyme inhibitor, captopril, in normotensive man. Clin Sci (Lond) 1985 Jan;68(1):49–56. [PubMed]
  • Cannon PJ. The kidney in heart failure. N Engl J Med. 1977 Jan 6;296(1):26–32. [PubMed]
  • Brown JJ, Davies DL, Johnson VW, Lever AF, Robertson JI. Renin relationships in congestive cardiac failure, treated and untreated. Am Heart J. 1970 Sep;80(3):329–342. [PubMed]
  • Hall JE, Guyton AC, Jackson TE, Coleman TG, Lohmeier TE, Trippodo NC. Control of glomerular filtration rate by renin-angiotensin system. Am J Physiol. 1977 Nov;233(5):F366–F372. [PubMed]
  • Kramer BL, Massie BM, Topic N. Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study. Circulation. 1983 Apr;67(4):807–816. [PubMed]
  • Nicholls MG, Ikram H, Espiner EA, Maslowski AH, Scandrett MS, Penman T. Hemodynamic and hormonal responses during captopril therapy for heart failure: acute, chronic and withdrawal studies. Am J Cardiol. 1982 Apr 21;49(6):1497–1501. [PubMed]
  • Sharpe DN, Murphy J, Coxon R, Hannan SF. Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Circulation. 1984 Aug;70(2):271–278. [PubMed]
  • Franciosa JA, Wilen MM, Jordan RA. Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure. J Am Coll Cardiol. 1985 Jan;5(1):101–107. [PubMed]
  • Cleland JG, Dargie HJ, Hodsman GP, Ball SG, Robertson JI, Morton JJ, East BW, Robertson I, Murray GD, Gillen G. Captopril in heart failure. A double blind controlled trial. Br Heart J. 1984 Nov;52(5):530–535. [PMC free article] [PubMed]
  • Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978 Dec;58(6):1072–1083. [PubMed]
  • Spodick DH, Doi YL, Bishop RL, Hashimoto T. Systolic time intervals reconsidered. Reevaluation of the preejection period: absence of relation to heart rate. Am J Cardiol. 1984 Jun 1;53(11):1667–1670. [PubMed]
  • Atkinson AB, Morton JJ, Brown JJ, Davies DL, Fraser R, Kelly P, Leckie B, Lever AF, Robertson JI. Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition. Br Heart J. 1980 Sep;44(3):290–296. [PMC free article] [PubMed]
  • Fraser R, Guest S, Young J. A comparison of double-isotope derivative and radioimmunological estimation of plasma aldosterone concentration in man. Clin Sci Mol Med. 1973 Sep;45(3):411–415. [PubMed]
  • Ball SG, Tree M, Morton JJ, Inglis GC, Fraser R. Circulating dopamine: its effect on the plasma concentrations of catecholamines, renin, angiotensin, aldosterone and vasopressin in the conscious dog. Clin Sci (Lond) 1981 Oct;61(4):417–422. [PubMed]
  • Boddy K, King PC, Hume R, Weyers E. The relation of total body potassium to height, weight, and age in normal adults. J Clin Pathol. 1972 Jun;25(6):512–517. [PMC free article] [PubMed]
  • Boddy K, Brown JJ, Davies DL, Elliott A, Harvey I, Haywood JK, Holloway I, Lever AF, Robertson JI, Williams ED. Concurrent estimation of total body and exchangeable body sodium in hypertension. Clin Sci Mol Med. 1978 Feb;54(2):187–191. [PubMed]
  • Ellis KJ, Vaswani A, Zanzi I, Cohn SH. Total body sodium and chlorine in normal adults. Metabolism. 1976 Jun;25(6):645–654. [PubMed]
  • Williams ED, Boddy K, Harvey I, Haywood JK. Calibration and evaluation of a system of total body in vivo activation analysis using 14 MeV neutrons. Phys Med Biol. 1978 May;23(3):405–415. [PubMed]
  • Chantler C, Garnett ES, Parsons V, Veall N. Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA. Clin Sci. 1969 Aug;37(1):169–180. [PubMed]
  • Tauxe WN, Maher FT, Taylor WF. Effective renal plasma flow: estimation from theoretical volumes of distribution of intravenously injected 131-I orthoiodohippurate. Mayo Clin Proc. 1971 Aug;46(8):524–531. [PubMed]
  • Cleland J, Semple P, Hodsman P, Ball S, Ford I, Dargie H. Angiotensin II levels, hemodynamics, and sympathoadrenal function after low-dose captopril in heart failure. Am J Med. 1984 Nov;77(5):880–886. [PubMed]
  • Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981 Dec;91(3):457–465. [PubMed]
  • Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982 Nov-Dec;4(6):966–972. [PubMed]
  • Glänzer K, Prüssing B, Düsing R, Kramer HJ. Hemodynamic and hormonal responses to 8-arginine-vasopressin in healthy man: effects of indomethacin. Klin Wochenschr. 1982 Oct 1;60(19):1234–1239. [PubMed]
  • Miller RR, Awan NA, Maxwell KS, Mason DT. Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin. N Engl J Med. 1977 Aug 11;297(6):303–307. [PubMed]
  • Mujais SK, Fouad FM, Textor SC, Tarazi RC, Bravo EL, Hart N, Gifford RW., Jr Transient renal dysfunction during initial inhibition of converting enzyme in congestive heart failure. Br Heart J. 1984 Jul;52(1):63–71. [PMC free article] [PubMed]
  • Holmes J, Kubo SH, Cody RJ, Kligfield P. Arrhythmias in ischemic and nonischemic dilated cardiomyopathy: prediction of mortality by ambulatory electrocardiography. Am J Cardiol. 1985 Jan 1;55(1):146–151. [PubMed]
  • Unverferth DV, Magorien RD, Moeschberger ML, Baker PB, Fetters JK, Leier CV. Factors influencing the one-year mortality of dilated cardiomyopathy. Am J Cardiol. 1984 Jul 1;54(1):147–152. [PubMed]
  • Franciosa JA, Wilen M, Ziesche S, Cohn JN. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1983 Mar 1;51(5):831–836. [PubMed]
  • Britton KE. Essential hypertension: a disorder of cortical nephron control. Lancet. 1981 Oct 24;2(8252):900–902. [PubMed]
  • Myers BD, Deen WM, Brenner BM. Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat. Circ Res. 1975 Jul;37(1):101–110. [PubMed]
  • Atkinson AB, Robertson JI. Captopril in the treatment of clinical hypertension and cardiac failure. Lancet. 1979 Oct 20;2(8147):836–839. [PubMed]
  • Ader R, Chatterjee K, Ports T, Brundage B, Hiramatsu B, Parmley W. Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor. Circulation. 1980 May;61(5):931–937. [PubMed]
  • Hodsman GP, Isles CG, Murray GD, Usherwood TP, Webb DJ, Robertson JI. Factors related to first dose hypotensive effect of captopril: prediction and treatment. Br Med J (Clin Res Ed) 1983 Mar 12;286(6368):832–834. [PMC free article] [PubMed]
  • Cody RJ, Covit AB, Schaer GL, Laragh JH. Evaluation of a long-acting converting enzyme inhibitor (enalapril) for the treatment of chronic congestive heart failure. J Am Coll Cardiol. 1983 Apr;1(4):1154–1159. [PubMed]
  • DiCarlo L, Chatterjee K, Parmley WW, Swedberg K, Atherton B, Curran D, Cucci M. Enalapril: a new angiotensin-converting enzyme inhibitor in chronic heart failure: acute and chronic hemodynamic evaluations. J Am Coll Cardiol. 1983 Nov;2(5):865–871. [PubMed]

Articles from British Heart Journal are provided here courtesy of BMJ Group